Navigation Links
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Date:7/5/2009

well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit: www.novabaypharma.com.

Forward-Looking Statements

The statements in this press release regarding NovaBay's and Alcon's expectations regarding the clinical trial and the potential efficacy of Aganocide(R) compounds are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward- looking statements reflect the views of the management of NovaBay and Alcon as of the date of this press release with respect to future events and are based on assumptions and subject to significant risks and uncertainties (many of which are outside of NovaBay's or Alcon's control), including the risk that FDA or other regulatory review may delay or prevent the development of Aganocide(R) compounds, and those detailed in the NovaBay's and Alcon's filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.; Alcon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ORBIS and Alcon Call Attention to the Aging Eye
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
6. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Cytopia Commences Second Phase II Study in Brain Cancer
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...MINGHAM,Mass.andSYDNEY,Nov.25/PRNewswire-FirstCall...IN),aleadinginnovatorandprovideroflessinvasive,min...zingthetreatmentofadvancedheartfailure,todayannoun...the21stAnnualPiperJaffrayHealthCareConferenceat8:0...ingheldattheNewYorkPalaceHotel,December1-2. ,, ...
(Date:11/24/2009)...HESDA,Md.,Nov.24/PRNewswire-Asia/--ChindexInternat...pendentAmericanproviderofWestern,healthcareproduct...ouncedthattheCompanywillattendthe21stAnnualPiperJa...mber1-2,2009,atthe,NewYorkPalaceHotel. , Mana...esday,December1,2009,andholdone-on-onemeetingsthr...
(Date:11/24/2009)...INE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix...reatmentsforaorticdisorders,announcedtodaythatitha...thepatentinfringementlawsuitbroughtagainstitinOcto...esDistrictCourtinIndianapolis,Indiana. ,, Endol...nitedStatesPatentandTrademarkOffice(USPTO)conducts...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2The Leapfrog Group Announces New Board Chair 50087 1The Leapfrog Group Announces New Board Chair 50087 2The Leapfrog Group Announces New Board Chair 50087 3Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 1Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 2Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 3Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 4Supply of Key Childrens Vaccine Almost Back to Normal 50081 1Supply of Key Childrens Vaccine Almost Back to Normal 50081 2Supply of Key Childrens Vaccine Almost Back to Normal 50081 3
...NESS WIRE)--May 17, 2007 - Results,published this ...er,vaccine, GARDASIL (Quadrivalent Human Papilloma...as 100 percent effective in,preventing high-grade ...16 and 18, two types strongly associated with thes...d in women who were not,infected with HPV types ta...
...th International Symposium on,Myelodysplastic Synd...ew updated results,from a pivotal Phase II trial e...lood cancer known as myelodysplastic syndromes (MD... H. Lee Moffitt,Cancer Center & Research Insti...rrently taking place in Florence, Italy.,Breakthro...
Other Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3
(Date:11/25/2009)...v.25/PRNewswire/-SentinelleMedicalInc.,aleadingman...oftwarelaunchesasuiteofnewleadingedgeclinicalappli...matthisyear,sRadiologicalSocietyofNorthAmerica(RSN...00,HallA).Theapplicationsleveragetheuniquehighqual...ingcoilsandsupportmultipleimagingmodalitiesformult...
(Date:11/25/2009)...,Nov.25/PRNewswire-USNewswire/--TheBlackAIDSInstit...executiveleadershipfor2010. ,, ThenewBoardMembe...publicpolicy,law,finance,governmenthealthprograms,...comesfromawiderangeofpersonalbackgroundsincludingb...thHIVthemselves,andrepresentingmultipleagegroups. ...
(Date:11/25/2009)...ors of testicular cancer who were treated with cis...ects, including neurological side effects and Rayn...with chemotherapy, according to a new study publis...onal Cancer Institute . , Marianne Brydy, M.D., ...y Hospital, in Bergen, Norway, and colleagues cond...
(Date:11/25/2009)...ease blood pressure? This simple question has bee...ew Stress-related gene Modulates High Blood Pressu...sure? This simple question has been the focus of ... has for the first time established a link between...esponse to stress in mice as well as humans. The s...
(Date:11/25/2009)... Evaluation and treatment clinics to resume...ock (Vocus) November 25, 2009 -- Centegra Health S...nd H1N1 vaccine shots at four Centegra Primary Car... of vaccine has arrived. The clinics are at CPC si...y and will be open as follows: ,   Fro...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...ournal Health Psychology, by the American Psycholo...with a short temper or mean disposition tend to h...sted even after asthma and smoking were ruled out ...onary Artery Risk Development in (Young) Adults St...
...and a radiation oncologist at Memorial Sloan-Kette... physician patients see can influence the type of...ed men with localized prostate cancer. It found th...a radiation oncologist and an urologist, usually r...
... of Clinical Oncology today, the results of a larg...undwork for decisions that included when or if a ... In patients with metastatic colorectal ca...s necessary. Few studies have examined the...
..., even if it is all subtle, as in Canada apparentl...ard to pin down is more dangerous to mental health...of 180 Korean immigrants living in Canada. ...d author Samuel Noh, professor of psychiatry at th...
...ase, a pair of young US researchers say. The more ...marriage . And never mind the quality of marital l...m Adrianne Frech, a sociology graduate student at ...for depression once in either 1987 or 1988 and the...
...ganizations (AAPPO) is launching a new initiative ...re to those patients diagnosed with diabetes as w...isease. An industry leader, AAPPO today kicked off...iabetes by providing tools and information to the ...
Other Medicine News:Health News:Unhealthy Lungs Linked to Hostility? 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 3Health News:Change in Course of Treatment: Exploring Better Ways 2Health News:Koreans in Canada Feel Put Down by Subtle Racism 2Health News:Marriage Could Lift One Out of Depression, New Study 2Health News:AAPPO Launches ACT on Diabetes Initiative to Promote Improved Diabetes Care 2
...higher risk diabetic patient, the PneumaticWalker ...iabetics. Similar to the PneumaticWalker, the Pneu...ve dual density insole to eliminate pressure point...shell and full aircell coverage, also helps regula...
...ce is designed for the treatment of diaphyseal fra...rovides post operative support following intra m...al fixation. The brace allows for movement of join...ascularity and encouraging bone growth. For a more...
...tem for the treatment of injuries of the lower leg...forms to the patient's anatomy and in conjunction ...ilization. As the general time of fracture or rupt...es of treatment can be altered significantly. Exce...
...nefits of controlled compression to minimize hemar...he cuff is anatomically designed to completely fit...o/Cuffs can be ordered as a single cuff, or with a...disk). The Cooler is available separately and can ...
Medicine Products: